Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for MSA patients: drug may reduce dizzy spells and falls

NCT ID NCT02071459

Symptom relief Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called droxidopa (L-threo DOPS) in 107 adults with multiple system atrophy (MSA) who experience dizziness or fainting when standing up due to low blood pressure. Participants received either the drug or a placebo for 12 weeks. The goal was to see if the drug could reduce these symptoms and improve daily life. The trial is complete, and results help doctors understand if this treatment is helpful for managing this challenging symptom.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

107 people

The number who actually took part.

Started

Jan 2014

Finished

Oct 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * MSA patients (possible or probable, MSA-P or C (according to revised criteria, Gilman et al 2008)). * Aged 30 to 80 years, * Able to walk at least 10 meters * With symptomatic OH (score of at least 3 at one of the items of Part I of the OH scale (OHQ)) * Documented fall in systolic blood pressure of at least 20 mmHg, and/or in diastolic blood pressure of at least 10 mmHg, within 3 minutes after standing. * Able to fill in the evaluation questionnaires with or without help * With no significant problems with swallowing. * Stable anti-parkinsonian, dysautonomia and depression treatments for the 4 weeks before the study and during the entire study * Signed written informed consent for the present study. Exclusion Criteria: * Dementia (DSM-IV, Mini-Mental State Examination (MMSE) \< 24/30) * Concomitant use of vaso-constrictive drugs, other than midodrine. Patients taking vasoconstrictor agents such as ephedrine, dihydroergotamine, must stop taking these drugs at least 2 days or 7 half-lives prior to their baseline visit (Visit 1); the association with midodrine may be kept at a stable dose not exceeding 3 tablets (7.5 mg) / day if the patient has no CV history. This will be discussed case by case with the coordinating center and the safety committee of this study. * Taking anti-hypertensive medication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple system atrophy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hypotension, Orthostatic multiple system atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple system atrophy

Contacts and locations

Locations

  • CHRU de lille

    Lille, 59037, France

  • CHU Pontchaillou

    Rennes, 35033, France

  • CHU bordeaux

    Bordeaux, France

  • CHU de Clermont-Ferrand

    Clermont-Ferrand, 63000, France

  • CHU de Dijon

    Dijon, 21000, France

  • CHU de Poitiers

    Poitiers, 86021, France

  • CHU de Rouen

    Rouen, 76031, France

  • CHU de limoges

    Limoges, 87042, France

  • Centre hospitalier d'Angers

    Angers, 49933, France

  • Hôpital G. & R. Laennec

    Nantes, 44093, France

  • Hôpital La Timone

    Marseille, 13000, France

  • Hôpital Pitié-Salpétrière

    Paris, 75013, France

  • chu de Strasbourg

    Strasbourg, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.